The Long Term Outcomes of Rehabilitation and Drug Treatment for in Urgency Urinary Incontinence
- Conditions
- Urge Urinary Incontinence
- Registration Number
- NCT00498888
- Lead Sponsor
- Assuta Hospital Systems
- Brief Summary
* Urinary Urge Incontinence (UUI) is the involuntary urine loss associated with a strong sensation to void.
* UUI usually associated with reduced bladder capacity.
* The pathophysiology is unclear.
* Pelvic floor muscle dysfunction and detrusor instability have been suggested as possible mechanisms.
* Standard treatment includes anticholinergic medication and behavior modification.
* The study aims to compare the long term effectiveness of 4 different approaches to the treatment of women with Urge Urinary Incontinence (UUI):
1. Pelvic Floor Rehabilitation (includes muscle training+behavioral intervention+bladder training)
2. Pelvic Floor muscle training alone
3. Bladder Training alone
4. Drug treatment with Tolterodine.
* Study variables will include: impairment ratings, quality of life, and cost-effectiveness.
* This study addresses three issues:
1. The long term efficacy and cost-effectiveness of the various treatment options.
2. To identify the factors involved in determining the effectiveness of drug or behavioral therapy.
3. The pathophysiology of UUI. By subdividing the rehabilitation group into 3 arms, we hope to shed light on the mechanism of dysfunction. A better response in one group will help localize the problem to pelvic floor muscles or to detrusor instability.
- Detailed Description
The study has 3 phases: Before treatment (phase I), immediately after 3 months of treatment (phase II), and 1 year post-entry (phase III)
Women with UUI will be divided randomly into one of the four treatment groups. Every subject will participate in 4 visits. The drug group treatment consists of administration of tolterodine SR 4 mg daily for 3 months. Subjects who assigned to the pelvic floor rehabilitation, pelvic floor muscle training, and bladder training groups will be treated via 4 visits to a physical therapist, who is trained in the procedures. The chief researcher (RK) will be blinded to the treatment groups and will perform the outcome measures in all phases.
Study variables will include impairment ratings, quality of life, and cost-effectiveness
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 164
- complaints of urinary leakage > 3 in last month (not stress incontinence)
- functionally independent subjects
- urinary tract infection
- urogenital prolapse
- unstable diabetes
- neurological or psychiatric disease
- narrow angle glaucoma
- after colposuspension or sling surgery
- Mini Mental State Examination <24
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Number of micturitions in a 24 hour bladder diary and number of urge urinary incontinence episodes by subjects' reports per week. Phase I, II, and III
- Secondary Outcome Measures
Name Time Method cost-effectiveness 1 year Health service utilization 1 year underclothing pad use Phase I, II, and III change in physical activity and smoking Phase I, II, and III missed days at work 1 year Maximum voided volume, as obtained from 24 hours bladder diary Phase I, II, III side effects from list of 10 possible effects: dry mouth, constipation, side effects from list of 10 possible effects: dry mouth, constipation, sleepiness, fatigue, blurred vision, dizziness, urinary difficulty, tachycardia, headache and low back pain Phase I, II, and III quality of life measured by I-QoL Phase I, II, and III visual analogue scale (VAS) use in urogynecological research Phase I, II, and III Incontinence Severity Index (ISI) Phase I, II, and III functional status as measured by Late Life Function and Disability Instrument Phase I, II, and III Depression status as measured by Center for Epidemiological Studies Depression scale (CES-D) Phase I, II, and III Cost benefit 1 year Maximum voluntary contraction fo pelvic floor muscle, graded 1-5 by Oxford scale Phase I, II, and III
Trial Locations
- Locations (1)
Rehabilitation and Physical Therapy Center, Maccabi Healthcare Services
🇮🇱Rishon Le Zion, Israel
Rehabilitation and Physical Therapy Center, Maccabi Healthcare Services🇮🇱Rishon Le Zion, Israel